BASIS OF FINANCIAL STATEMENT PRESENTATION Novel Coronavirus (COVID-19) Financial Statement Impact (Policies)	3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]
Novel Coranvirus (Covid-19) Financial Statement Impact [Policy Text Block]	Novel Coronavirus (COVID-19) Financial Statement Impact In March 2020, the novel strain of coronavirus, now known as COVID-19, was declared a pandemic. The COVID-19 pandemic has and continues to have an extensive impact on the global health and economic environments. By mid-March 2020, government restrictions, social distancing guidelines, and overall customer caution associated with the COVID-19 pandemic negatively affected LCD’s revenues and CDD's operations. For LCD, reduction in demand impacted testing volumes broadly but was more heavily weighted towards routine tests. This reduction in demand impacted testing volumes broadly but was more heavily weighted towards routine tests. The performance of CDD has also been negatively affected by the COVID-19 pandemic through numerous study site closures around the world as well as customer initiated delays for new patient recruitment for existing clinical trials and start-up of new clinical trials. As a result of the impact of the COVID-19 pandemic, during the three months ended March 31, 2020, the Company recorded goodwill and other asset impairment charges of $437.4: $426.4 within CDD and $11.0 within LCD. See Note 6 Goodwill and Intangible Assets for discussion of goodwill and intangible asset impairment and Note 2 Revenue for the discussion of credit losses and additional price concessions. The Company also wrote-off or wrote down certain of the Company's investments by $20.2 due to the impact of COVID-19, $7.1 included in Equity method earnings (loss), net and $13.1 included in Other, net.

In March 2020, the novel strain of coronavirus, now known as COVID-19, was declared a pandemic. The COVID-19 pandemic has and continues to have an extensive impact on the global health and economic environments. By mid-March 2020, government restrictions, social distancing guidelines, and overall customer caution associated with the COVID-19 pandemic negatively affected LCD’s revenues and CDD's operations. For LCD, reduction in demand impacted testing volumes broadly but was more heavily weighted towards routine tests. This reduction in demand impacted testing volumes broadly but was more heavily weighted towards routine tests. The performance of CDD has also been negatively affected by the COVID-19 pandemic through numerous study site closures around the world as well as customer initiated delays for new patient recruitment for existing clinical trials and start-up of new clinical trials. As a result of the impact of the COVID-19 pandemic, during the three months ended March 31, 2020, the Company recorded goodwill and other asset impairment charges of $437.4: $426.4 within CDD and $11.0 within LCD. See Note 6 Goodwill and Intangible Assets for discussion of goodwill and intangible asset impairment and Note 2 Revenue for the discussion of credit losses and additional price concessions. The Company also wrote-off or wrote down certain of the Company's investments by $20.2 due to the impact of COVID-19, $7.1 included in Equity method earnings (loss), net and $13.1 included in Other, net.